Nektar Therapeutics (NKTR)
1.65
+0.08
(+5.10%)
USD |
NASDAQ |
May 06, 16:00
1.65
0.00 (0.00%)
Pre-Market: 20:00
Nektar Therapeutics Cash from Financing (TTM): 0.03M for Dec. 31, 2023
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
| Date | Value |
|---|---|
| December 31, 2023 | 0.03M |
| September 30, 2023 | 0.121M |
| June 30, 2023 | 0.121M |
| March 31, 2023 | 0.57M |
| December 31, 2022 | 1.508M |
| September 30, 2022 | 3.957M |
| June 30, 2022 | 7.62M |
| March 31, 2022 | 19.32M |
| December 31, 2021 | 36.24M |
| September 30, 2021 | 182.68M |
| June 30, 2021 | 180.55M |
| March 31, 2021 | -73.58M |
| December 31, 2020 | -80.35M |
| September 30, 2020 | -224.44M |
| June 30, 2020 | -219.72M |
| March 31, 2020 | 29.54M |
| December 31, 2019 | 23.36M |
| September 30, 2019 | 21.12M |
| June 30, 2019 | 18.73M |
| March 31, 2019 | 822.51M |
| December 31, 2018 | 851.97M |
| September 30, 2018 | 873.57M |
| June 30, 2018 | 879.18M |
| March 31, 2018 | 77.56M |
| December 31, 2017 | 54.39M |
| Date | Value |
|---|---|
| September 30, 2017 | 221.07M |
| June 30, 2017 | 218.14M |
| March 31, 2017 | 210.42M |
| December 31, 2016 | 203.62M |
| September 30, 2016 | 131.73M |
| June 30, 2016 | 131.60M |
| March 31, 2016 | 134.57M |
| December 31, 2015 | 130.78M |
| September 30, 2015 | 41.58M |
| June 30, 2015 | 42.39M |
| March 31, 2015 | 39.70M |
| December 31, 2014 | 152.98M |
| September 30, 2014 | 125.29M |
| June 30, 2014 | 119.97M |
| March 31, 2014 | 118.56M |
| December 31, 2013 | 2.216M |
| September 30, 2013 | 0.262M |
| June 30, 2013 | -94.82M |
| March 31, 2013 | -95.18M |
| December 31, 2012 | 26.80M |
| September 30, 2012 | 26.28M |
| June 30, 2012 | 119.50M |
| March 31, 2012 | 120.34M |
| December 31, 2011 | 222.34M |
| September 30, 2011 | 224.15M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
-224.44M
Minimum
Sep 2020
182.68M
Maximum
Sep 2021
-3.823M
Average
3.957M
Median
Sep 2022
Cash from Financing (TTM) Benchmarks
| Stereotaxis Inc | 0.081M |
| Vanda Pharmaceuticals Inc | -- |
| Cara Therapeutics Inc | 38.15M |
| Avid Bioservices Inc | 8.937M |
| Rigel Pharmaceuticals Inc | 18.37M |